首页 > 最新文献

Clinical and Experimental Neuroimmunology最新文献

英文 中文
A Thank You Note to Our Reviewers 给我们审稿人的感谢信
Q4 Immunology and Microbiology Pub Date : 2026-02-05 DOI: 10.1111/cen3.70048
{"title":"A Thank You Note to Our Reviewers","authors":"","doi":"10.1111/cen3.70048","DOIUrl":"https://doi.org/10.1111/cen3.70048","url":null,"abstract":"","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146139241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated With Poor Outcome Among Guillain Barre Syndrome Patients Admitted in a Tertiary Hospital in the Philippines: A Retrospective Cohort Study 菲律宾一家三级医院格林-巴利综合征患者预后不良的相关因素:一项回顾性队列研究
Q4 Immunology and Microbiology Pub Date : 2026-01-22 DOI: 10.1111/cen3.70047
Mario B. Prado Jr, Karen Joy B. Adiao, Iris Ditan, Lowrence Precious Dichoso, Gerald T. Pagaling

Objectives

Although a locally published paper clinically characterized Guillain Barre syndrome (GBS) patients admitted in one of the Philippines' largest hospitals, extensive identification of risk factors associated with poor outcomes has yet to be done. The main objective of this study is to determine the possible association between several outcome measures and GBS risk factors using different regression analytic methods of secondary data.

Methods

Data from 71 GBS patients from our previous study about possible determinants related to dysautonomia were analyzed. To determine the possible factors associated with binary outcomes like status on discharge, ambulation at 1 month, and presence or absence of pneumonia during admission, multiple logistic regression analysis was used while factors associated with continuous outcome like onset of motor recovery, multiple linear regression analysis was utilized. For failure outcomes with survival times, including days to dysautonomia or intubation, a cox proportional hazard model or its variants were utilized.

Results

Using dysautonomia as the main independent variable, and age and presence of pneumonia prior to GBS diagnosis as the possible confounders, no association between dysautonomia and different outcome parameters was noted whether unadjusted or adjusted odds ratio (OR) was used. Compared to other GBS variants, the odds of being bed or wheelchair bound on discharge was 10 times (95% CI: 1.7–57.7, p = 0.01) when a patient has the axonal variant of GBS. Moreover, the same cohort was 20 times (95% CI: 3.2–125.0, p < 0.01) more likely to be nonambulatory in 1 month when compared to other GBS variants. In terms of types of treatment, no association between the type of treatment and different outcome variables was noted whether uncontrolled or factors such as sex, days until admission, expanded disability status scale (EDSS) at admission, initial GBS-DS, presence of pneumonia, proportion of patients with Brighton diagnostic level 1, and GBS type were controlled.

Conclusion

In the Philippines, the type of GBS is found to be associated with poor prognosis. Nevertheless, when possible confounders were controlled, the type of GBS, dysautonomia, and type of treatment were noted not to affect the outcomes. The insufficient power of the study may explain the negative results of the commonly associated factors of poor prognosis.

尽管一篇在当地发表的论文对菲律宾一家最大的医院收治的格林-巴利综合征(GBS)患者进行了临床描述,但尚未对与不良预后相关的危险因素进行广泛识别。本研究的主要目的是利用不同的二次数据回归分析方法,确定几种结局指标与GBS危险因素之间可能存在的关联。方法对71例GBS患者的自主神经异常相关因素进行分析。为了确定与出院状态、1个月时的活动、入院时是否存在肺炎等二元结局相关的可能因素,采用多元logistic回归分析,而与运动恢复开始等连续结局相关的因素采用多元线性回归分析。对于带有生存时间的失败结果,包括到自主神经异常或插管的天数,使用cox比例风险模型或其变体。结果以自主神经异常为主要自变量,年龄和GBS诊断前是否存在肺炎为可能的混杂因素,无论使用未调整或调整的比值比(or),均未发现自主神经异常与不同结局参数之间的相关性。与其他GBS变体相比,当患者患有轴突型GBS时,出院时卧床或坐轮椅的几率是10倍(95% CI: 1.7-57.7, p = 0.01)。此外,与其他GBS变体相比,同一队列在1个月内无法走动的可能性高出20倍(95% CI: 3.2-125.0, p < 0.01)。在治疗类型方面,未注意到治疗类型与不同结果变量之间的关联,是否不受控制或诸如性别、入院前天数、入院时扩展残疾状态量表(EDSS)、初始GBS- ds、是否存在肺炎、布赖顿诊断水平为1的患者比例和GBS类型等因素受到控制。结论在菲律宾,GBS的类型与预后不良有关。然而,当可能的混杂因素得到控制时,注意到GBS的类型,自主神经异常和治疗类型不会影响结果。该研究的不足可能解释了不良预后的常见相关因素的阴性结果。
{"title":"Factors Associated With Poor Outcome Among Guillain Barre Syndrome Patients Admitted in a Tertiary Hospital in the Philippines: A Retrospective Cohort Study","authors":"Mario B. Prado Jr,&nbsp;Karen Joy B. Adiao,&nbsp;Iris Ditan,&nbsp;Lowrence Precious Dichoso,&nbsp;Gerald T. Pagaling","doi":"10.1111/cen3.70047","DOIUrl":"https://doi.org/10.1111/cen3.70047","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Although a locally published paper clinically characterized Guillain Barre syndrome (GBS) patients admitted in one of the Philippines' largest hospitals, extensive identification of risk factors associated with poor outcomes has yet to be done. The main objective of this study is to determine the possible association between several outcome measures and GBS risk factors using different regression analytic methods of secondary data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from 71 GBS patients from our previous study about possible determinants related to dysautonomia were analyzed. To determine the possible factors associated with binary outcomes like status on discharge, ambulation at 1 month, and presence or absence of pneumonia during admission, multiple logistic regression analysis was used while factors associated with continuous outcome like onset of motor recovery, multiple linear regression analysis was utilized. For failure outcomes with survival times, including days to dysautonomia or intubation, a cox proportional hazard model or its variants were utilized.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Using dysautonomia as the main independent variable, and age and presence of pneumonia prior to GBS diagnosis as the possible confounders, no association between dysautonomia and different outcome parameters was noted whether unadjusted or adjusted odds ratio (OR) was used. Compared to other GBS variants, the odds of being bed or wheelchair bound on discharge was 10 times (95% CI: 1.7–57.7, <i>p</i> = 0.01) when a patient has the axonal variant of GBS. Moreover, the same cohort was 20 times (95% CI: 3.2–125.0, <i>p</i> &lt; 0.01) more likely to be nonambulatory in 1 month when compared to other GBS variants. In terms of types of treatment, no association between the type of treatment and different outcome variables was noted whether uncontrolled or factors such as sex, days until admission, expanded disability status scale (EDSS) at admission, initial GBS-DS, presence of pneumonia, proportion of patients with Brighton diagnostic level 1, and GBS type were controlled.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In the Philippines, the type of GBS is found to be associated with poor prognosis. Nevertheless, when possible confounders were controlled, the type of GBS, dysautonomia, and type of treatment were noted not to affect the outcomes. The insufficient power of the study may explain the negative results of the commonly associated factors of poor prognosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146091309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profound Cognitive Impairment as a Salient Feature of Multiple Sclerosis: A Case Report 重度认知障碍是多发性硬化症的显著特征:1例报告
Q4 Immunology and Microbiology Pub Date : 2026-01-20 DOI: 10.1111/cen3.70046
Shota Ito, Madoka Iida, Yuki Fukami, Masahisa Katsuno

Background

Cognitive impairment affects up to two-thirds of patients with multiple sclerosis (MS); however, profound global deficits, defined as a full-scale IQ below 70, are uncommon and rarely constitute the primary symptom.

Case Presentation

We describe a 27-year-old woman with severe multidomain cognitive impairment due to MS. Neuropsychological testing showed marked slowing of processing speed and perceptual reasoning, while verbal abilities remained relatively preserved. Although such profound dysfunction is atypical, the cognitive profile remained typical of MS: prominent deficits in processing speed and perceptual reasoning with sparing of verbal abilities.

Conclusions

This case suggests that atypical MS with unrecognized cognitive dysfunction presents a diagnostic challenge.

认知障碍影响多达三分之二的多发性硬化症(MS)患者;然而,严重的全面缺陷,即全面智商低于70,并不常见,也很少构成主要症状。我们描述了一名27岁的女性,由于多发性硬化症导致严重的多领域认知障碍,神经心理学测试显示处理速度和知觉推理明显减慢,而语言能力相对保留。尽管这种严重的功能障碍是非典型的,但认知特征仍然是MS的典型特征:处理速度和知觉推理方面的显著缺陷,语言能力不足。结论本病例提示非典型MS伴认知功能障碍的诊断存在挑战。
{"title":"Profound Cognitive Impairment as a Salient Feature of Multiple Sclerosis: A Case Report","authors":"Shota Ito,&nbsp;Madoka Iida,&nbsp;Yuki Fukami,&nbsp;Masahisa Katsuno","doi":"10.1111/cen3.70046","DOIUrl":"https://doi.org/10.1111/cen3.70046","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cognitive impairment affects up to two-thirds of patients with multiple sclerosis (MS); however, profound global deficits, defined as a full-scale IQ below 70, are uncommon and rarely constitute the primary symptom.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>We describe a 27-year-old woman with severe multidomain cognitive impairment due to MS. Neuropsychological testing showed marked slowing of processing speed and perceptual reasoning, while verbal abilities remained relatively preserved. Although such profound dysfunction is atypical, the cognitive profile remained typical of MS: prominent deficits in processing speed and perceptual reasoning with sparing of verbal abilities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This case suggests that atypical MS with unrecognized cognitive dysfunction presents a diagnostic challenge.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen3.70046","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146099240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiple Sclerosis in Morocco: Impact on Patients' Quality of Life 摩洛哥多发性硬化症:对患者生活质量的影响
Q4 Immunology and Microbiology Pub Date : 2026-01-11 DOI: 10.1111/cen3.70044
Rachid Lotfi, Hind Bel Amgharia, Sami Ennaciri, Mourad Chikhaoui, Ahmed Chetoui, Jaouad Elkhalladi, Fatiha Chigr

Background

In multiple sclerosis (MS), health-related quality of life (HRQoL) is often impaired both physically and mentally. This study aimed to assess the dimensions of quality of life (QoL) most affected among patients with MS in Morocco.

Methods

This descriptive study included 152 patients from four Moroccan regions. Data were collected through an electronic survey. QoL was assessed using the Arabic version of the MS Quality of Life-54 (MSQOL-54) scale, a validated multidimensional tool specific to MS.

Results

Participants were mostly young women (mean age: 32.6 years), single, and with a university education. Overall, QoL was impaired, particularly in domains related to energy, physical and psychological limitations, and perceived health. Moderate distress, both physical and mental, was noted, along with significant emotional challenges. However, sexual function, cognitive function, and social relationships were relatively preserved. Statistically significant associations were found between QoL and sociodemographic factors such as gender, age, and the type of MS.

Conclusion

MS significantly impairs the QoL of Moroccan patients. Sociodemographic factors play a substantial role, warranting further investigation into the determinants of QoL.

背景:在多发性硬化症(MS)中,健康相关生活质量(HRQoL)经常在身体和精神上受到损害。本研究旨在评估摩洛哥MS患者中最受影响的生活质量(QoL)维度。方法本描述性研究纳入来自摩洛哥4个地区的152例患者。数据是通过电子调查收集的。生活质量使用阿拉伯语版MS生活质量-54 (MSQOL-54)量表进行评估,这是一种针对MS的经过验证的多维工具。结果参与者大多是年轻女性(平均年龄:32.6岁),单身,受过大学教育。总体而言,生活质量受损,特别是在与能量、身心限制和感知健康有关的领域。他们注意到中度的身体和精神上的痛苦,以及严重的情感挑战。然而,性功能、认知功能和社会关系相对保存。生活质量与性别、年龄、MS类型等社会人口学因素存在显著相关性。结论MS显著影响摩洛哥患者的生活质量。社会人口因素发挥了重要作用,需要进一步调查生活质量的决定因素。
{"title":"Multiple Sclerosis in Morocco: Impact on Patients' Quality of Life","authors":"Rachid Lotfi,&nbsp;Hind Bel Amgharia,&nbsp;Sami Ennaciri,&nbsp;Mourad Chikhaoui,&nbsp;Ahmed Chetoui,&nbsp;Jaouad Elkhalladi,&nbsp;Fatiha Chigr","doi":"10.1111/cen3.70044","DOIUrl":"https://doi.org/10.1111/cen3.70044","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In multiple sclerosis (MS), health-related quality of life (HRQoL) is often impaired both physically and mentally. This study aimed to assess the dimensions of quality of life (QoL) most affected among patients with MS in Morocco.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This descriptive study included 152 patients from four Moroccan regions. Data were collected through an electronic survey. QoL was assessed using the Arabic version of the MS Quality of Life-54 (MSQOL-54) scale, a validated multidimensional tool specific to MS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Participants were mostly young women (mean age: 32.6 years), single, and with a university education. Overall, QoL was impaired, particularly in domains related to energy, physical and psychological limitations, and perceived health. Moderate distress, both physical and mental, was noted, along with significant emotional challenges. However, sexual function, cognitive function, and social relationships were relatively preserved. Statistically significant associations were found between QoL and sociodemographic factors such as gender, age, and the type of MS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MS significantly impairs the QoL of Moroccan patients. Sociodemographic factors play a substantial role, warranting further investigation into the determinants of QoL.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146002016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Seronegative CCPD Misclassified as MS: A Practical Lesson in B-Cell-Driven Disease Stabilized With Rituximab 血清阴性CCPD误诊为多发性硬化症:利妥昔单抗稳定b细胞驱动疾病的实践经验
Q4 Immunology and Microbiology Pub Date : 2026-01-07 DOI: 10.1111/cen3.70045
Ozan Dörtkol, Zeynep Kara, Bade Güleç, Arife Çimen Atalar, Aysel Tekeşin

Background

Combined central and peripheral demyelination (CCPD) is a rare immune-mediated disorder involving both central and peripheral myelin. Recent evidence suggests that CCPD may represent a distinct clinical and immunological entity rather than a coincidental overlap between multiple sclerosis (MS) and chronic inflammatory demyelinating polyneuropathy (CIDP).

Case Presentation

We report a 63-year-old seronegative female patient who had initially been followed with a diagnosis of MS and was later re-evaluated as having CCPD after developing new peripheral symptoms. Cerebrospinal fluid analysis revealed elevated protein levels with negative oligoclonal bands. Autoantibody screening, including anti-MOG, anti-MAG, AQP4, and NF155, was negative. MRI showed confluent periventricular and juxtacortical lesions consistent with central involvement. The patient showed clinical stability with no further radiological progression after rituximab therapy over an 8-month follow-up period.

Conclusion

This case supports the existence of a seronegative, B-cell-mediated variant of CCPD and highlights the potential role of rituximab in achieving disease stabilization. Recognition of CCPD as a distinct diagnostic entity may prevent misclassification as MS and guide appropriate immunotherapy strategies.

背景:联合中枢和外周脱髓鞘(CCPD)是一种罕见的涉及中枢和外周髓鞘的免疫介导疾病。最近的证据表明,CCPD可能代表一种独特的临床和免疫学实体,而不是多发性硬化症(MS)和慢性炎症性脱髓鞘性多神经病变(CIDP)之间的巧合重叠。我们报告了一位63岁的血清阴性女性患者,她最初被诊断为多发性硬化症,后来在出现新的周围症状后被重新评估为CCPD。脑脊液分析显示蛋白水平升高,呈阴性寡克隆带。自身抗体筛选,包括抗mog、抗mag、AQP4和NF155均为阴性。MRI显示合流性脑室周围和皮质旁病变与中枢性受累一致。患者在接受利妥昔单抗治疗8个月后,临床表现稳定,放射学无进一步进展。结论该病例支持血清阴性、b细胞介导的CCPD变体的存在,并强调了利妥昔单抗在实现疾病稳定中的潜在作用。认识到CCPD是一种独特的诊断实体,可以防止误诊为MS,并指导适当的免疫治疗策略。
{"title":"A Seronegative CCPD Misclassified as MS: A Practical Lesson in B-Cell-Driven Disease Stabilized With Rituximab","authors":"Ozan Dörtkol,&nbsp;Zeynep Kara,&nbsp;Bade Güleç,&nbsp;Arife Çimen Atalar,&nbsp;Aysel Tekeşin","doi":"10.1111/cen3.70045","DOIUrl":"https://doi.org/10.1111/cen3.70045","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Combined central and peripheral demyelination (CCPD) is a rare immune-mediated disorder involving both central and peripheral myelin. Recent evidence suggests that CCPD may represent a distinct clinical and immunological entity rather than a coincidental overlap between multiple sclerosis (MS) and chronic inflammatory demyelinating polyneuropathy (CIDP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>We report a 63-year-old seronegative female patient who had initially been followed with a diagnosis of MS and was later re-evaluated as having CCPD after developing new peripheral symptoms. Cerebrospinal fluid analysis revealed elevated protein levels with negative oligoclonal bands. Autoantibody screening, including anti-MOG, anti-MAG, AQP4, and NF155, was negative. MRI showed confluent periventricular and juxtacortical lesions consistent with central involvement. The patient showed clinical stability with no further radiological progression after rituximab therapy over an 8-month follow-up period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This case supports the existence of a seronegative, B-cell-mediated variant of CCPD and highlights the potential role of rituximab in achieving disease stabilization. Recognition of CCPD as a distinct diagnostic entity may prevent misclassification as MS and guide appropriate immunotherapy strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145963884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reconsidering Obinutuzumab: A Review of Type II Anti-CD20 Antibodies in Immunological Disorders of the Nervous System 重新考虑Obinutuzumab: II型抗cd20抗体在神经系统免疫性疾病中的研究综述
Q4 Immunology and Microbiology Pub Date : 2025-12-15 DOI: 10.1111/cen3.70043
Naif Alsaber, Sultan Alshehri, Osama Khairoalsindi, Abdulhameed Alsaawi

Anti-CD20 monoclonal antibodies (mAbs) are among the most widely used cytoreductive therapies for B-cell-mediated diseases. Type I anti-CD20 mAbs, including rituximab and ocrelizumab, primarily act through complement-dependent cytotoxicity, whereas type II agents such as obinutuzumab (OBZ) achieve B-cell depletion mainly via antibody-dependent cellular cytotoxicity. Despite targeting the same CD20 antigen, these subclasses differ in molecular interactions, effector mechanisms, and possibly in clinical outcomes. This review synthesizes preclinical and clinical evidence on OBZ in immune-mediated disorders of the nervous system. A structured literature search from inception to April 2025 identified descriptive studies and case reports suggesting clinical benefit of OBZ in myelin-associated glycoprotein-related neuropathy, paraneoplastic neuromyelitis optica spectrum disorder, myasthenia gravis, and rituximab-refractory autoimmune encephalitis. Preclinical work in murine models of experimental autoimmune encephalomyelitis further indicates enhanced B-cell depletion and neuroprotection relative to rituximab. Collectively, the available evidence remains preliminary but suggests that OBZ may offer therapeutic advantages in selected neuroimmunological disorders, particularly where complement dependence or rituximab refractoriness limits efficacy. Nevertheless, controlled clinical trials are warranted to clarify its safety and therapeutic role in antibody-mediated neurological diseases.

抗cd20单克隆抗体(mab)是b细胞介导疾病最广泛使用的细胞减少疗法之一。I型抗cd20单抗,包括利妥昔单抗和奥克雷单抗,主要通过补体依赖性细胞毒性起作用,而II型药物,如obinutuzumab (OBZ),主要通过抗体依赖性细胞毒性实现b细胞耗竭。尽管靶向相同的CD20抗原,但这些亚类在分子相互作用、效应机制以及可能的临床结果方面存在差异。本文综述了OBZ在免疫介导的神经系统疾病中的临床前和临床证据。从开始到2025年4月的结构化文献检索确定了描述性研究和病例报告,表明OBZ在髓磷脂相关的糖蛋白相关神经病变、副肿瘤神经脊髓炎视谱障碍、重症肌无力和利图昔单抗难治性自身免疫性脑炎中的临床益处。实验性自身免疫性脑脊髓炎小鼠模型的临床前研究进一步表明,与利妥昔单抗相比,b细胞耗竭和神经保护作用增强。总的来说,现有的证据仍然是初步的,但表明OBZ可能在某些神经免疫疾病中具有治疗优势,特别是在补体依赖或利妥昔单抗难治性限制疗效的情况下。然而,对照临床试验有必要阐明其在抗体介导的神经系统疾病中的安全性和治疗作用。
{"title":"Reconsidering Obinutuzumab: A Review of Type II Anti-CD20 Antibodies in Immunological Disorders of the Nervous System","authors":"Naif Alsaber,&nbsp;Sultan Alshehri,&nbsp;Osama Khairoalsindi,&nbsp;Abdulhameed Alsaawi","doi":"10.1111/cen3.70043","DOIUrl":"https://doi.org/10.1111/cen3.70043","url":null,"abstract":"<div>\u0000 \u0000 <p>Anti-CD20 monoclonal antibodies (mAbs) are among the most widely used cytoreductive therapies for B-cell-mediated diseases. Type I anti-CD20 mAbs, including rituximab and ocrelizumab, primarily act through complement-dependent cytotoxicity, whereas type II agents such as obinutuzumab (OBZ) achieve B-cell depletion mainly via antibody-dependent cellular cytotoxicity. Despite targeting the same CD20 antigen, these subclasses differ in molecular interactions, effector mechanisms, and possibly in clinical outcomes. This review synthesizes preclinical and clinical evidence on OBZ in immune-mediated disorders of the nervous system. A structured literature search from inception to April 2025 identified descriptive studies and case reports suggesting clinical benefit of OBZ in myelin-associated glycoprotein-related neuropathy, paraneoplastic neuromyelitis optica spectrum disorder, myasthenia gravis, and rituximab-refractory autoimmune encephalitis. Preclinical work in murine models of experimental autoimmune encephalomyelitis further indicates enhanced B-cell depletion and neuroprotection relative to rituximab. Collectively, the available evidence remains preliminary but suggests that OBZ may offer therapeutic advantages in selected neuroimmunological disorders, particularly where complement dependence or rituximab refractoriness limits efficacy. Nevertheless, controlled clinical trials are warranted to clarify its safety and therapeutic role in antibody-mediated neurological diseases.</p>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145824660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case of AQP4 Antibody–Positive NMOSD Initially Manifesting as Extensive, Asymptomatic Cerebral White Matter Lesions and Subsequently Developing Cognitive Impairment AQP4抗体阳性的NMOSD 1例,最初表现为广泛的无症状脑白质病变,随后发展为认知障碍
Q4 Immunology and Microbiology Pub Date : 2025-12-08 DOI: 10.1111/cen3.70041
Takafumi Hosokawa, Shin Ota, Manami Matsushita, Takahiro Akamatsu, Shoji Ogawa, Taiki Sawai, Yukiyo Yoshimoto, Yoshitsugu Nakamura, Akira Higashiyama, Shigeki Arawaka

Background

The original diagnostic criteria for neuromyelitis optica (NMO) required both optic neuritis and myelitis. The subsequent recognition of cases with either one of these features or other central nervous system lesions, including brain involvement, gave rise to the concept of NMO spectrum disorder (NMOSD). Cerebral involvement has been reported in various forms, including extensive lesions, asymptomatic lesions, and cases in which brain pathology represents the initial clinical manifestation. Despite this, asymptomatic individuals are not currently included within the 2015 NMOSD diagnostic criteria.

Case Presentation

A 74-year-old man was referred to our hospital due to abnormal findings on brain MRI, despite the absence of neurological deficits. Brain magnetic resonance imaging (MRI) demonstrated multifocal extensive cerebral white matter lesions with multiple ill-defined, patchy, mild, and irregular gadolinium-enhancing lesions, consistent with “cloud-like enhancement.” Aquaporin-4 (AQP4) antibodies were negative by enzyme-linked immunosorbent assay (ELISA) but positive on a cell-based assay (CBA). At that time, the patient was asymptomatic and therefore did not meet the diagnostic criteria for NMOSD. After exhaustive exclusion of alternative diagnoses and the subsequent development of cognitive impairment, the patient was diagnosed with NMOSD.

Conclusions

To our knowledge, this is the first reported case in which extensive, asymptomatic cerebral white matter lesions served as the initial manifestation of NMOSD, emphasizing the clinical importance of considering such cases in the differential diagnosis, evaluating appropriate treatment strategies, and potentially informing future revisions of the NMOSD diagnostic criteria.

背景视神经脊髓炎(NMO)最初的诊断标准是视神经炎和脊髓炎。随后对具有这些特征之一或其他中枢神经系统病变(包括脑受损伤)的病例的识别,产生了NMO谱系障碍(NMOSD)的概念。据报道,脑受累的形式多种多样,包括广泛的病变,无症状的病变,以及以脑病理为初始临床表现的病例。尽管如此,无症状个体目前并未包括在2015年NMOSD诊断标准中。病例介绍一名74岁男性,尽管没有神经功能缺陷,但由于脑部MRI异常发现而转介到我院。脑磁共振成像(MRI)显示多灶性广泛脑白质病变,伴多处模糊、斑片状、轻度、不规则钆增强病灶,符合“云样强化”。酶联免疫吸附试验(ELISA)显示Aquaporin-4 (AQP4)抗体为阴性,但基于细胞的试验(CBA)显示阳性。当时,患者无症状,因此不符合NMOSD的诊断标准。在彻底排除其他诊断和随后的认知障碍发展后,患者被诊断为NMOSD。据我们所知,这是首次报道广泛的无症状脑白质病变作为NMOSD的初始表现,强调了在鉴别诊断中考虑此类病例的临床重要性,评估适当的治疗策略,并可能为未来修订NMOSD诊断标准提供信息。
{"title":"A Case of AQP4 Antibody–Positive NMOSD Initially Manifesting as Extensive, Asymptomatic Cerebral White Matter Lesions and Subsequently Developing Cognitive Impairment","authors":"Takafumi Hosokawa,&nbsp;Shin Ota,&nbsp;Manami Matsushita,&nbsp;Takahiro Akamatsu,&nbsp;Shoji Ogawa,&nbsp;Taiki Sawai,&nbsp;Yukiyo Yoshimoto,&nbsp;Yoshitsugu Nakamura,&nbsp;Akira Higashiyama,&nbsp;Shigeki Arawaka","doi":"10.1111/cen3.70041","DOIUrl":"https://doi.org/10.1111/cen3.70041","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The original diagnostic criteria for neuromyelitis optica (NMO) required both optic neuritis and myelitis. The subsequent recognition of cases with either one of these features or other central nervous system lesions, including brain involvement, gave rise to the concept of NMO spectrum disorder (NMOSD). Cerebral involvement has been reported in various forms, including extensive lesions, asymptomatic lesions, and cases in which brain pathology represents the initial clinical manifestation. Despite this, asymptomatic individuals are not currently included within the 2015 NMOSD diagnostic criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>A 74-year-old man was referred to our hospital due to abnormal findings on brain MRI, despite the absence of neurological deficits. Brain magnetic resonance imaging (MRI) demonstrated multifocal extensive cerebral white matter lesions with multiple ill-defined, patchy, mild, and irregular gadolinium-enhancing lesions, consistent with “cloud-like enhancement.” Aquaporin-4 (AQP4) antibodies were negative by enzyme-linked immunosorbent assay (ELISA) but positive on a cell-based assay (CBA). At that time, the patient was asymptomatic and therefore did not meet the diagnostic criteria for NMOSD. After exhaustive exclusion of alternative diagnoses and the subsequent development of cognitive impairment, the patient was diagnosed with NMOSD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>To our knowledge, this is the first reported case in which extensive, asymptomatic cerebral white matter lesions served as the initial manifestation of NMOSD, emphasizing the clinical importance of considering such cases in the differential diagnosis, evaluating appropriate treatment strategies, and potentially informing future revisions of the NMOSD diagnostic criteria.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Treatment of Refractory Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease With Tocilizumab: A Case Report and Literature Review 托珠单抗成功治疗难治性髓鞘少突胶质细胞糖蛋白抗体相关疾病:1例报告和文献综述
Q4 Immunology and Microbiology Pub Date : 2025-12-07 DOI: 10.1111/cen3.70040
Takahiko Katsuyama, Ryohei Horiguchi, Yuki Matsunaga, Akihiro Nishimachi, Keisuke Morihara, Hideyuki Takeuchi

Background

Approximately half of patients with myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) experience relapses, and optimal relapse-prevention strategies remain under discussion. The interleukin-6 (IL-6) signaling pathway plays a pivotal role in MOGAD pathogenesis, and its inhibition has been proposed as a promising therapeutic approach.

Case Presentation

We describe an 18-year-old male with refractory MOGAD characterized by multiple MRI-detected lesions showing an acute disseminated encephalomyelitis (ADEM)-like pattern, whose condition dramatically improved with tocilizumab. His symptoms included fever, headache, nausea, paresthesia, moria, somnolence, and seizure. Despite multiple courses of intravenous methylprednisolone, plasma exchange, and intravenous immunoglobulin, his condition remained uncontrolled. Weekly subcutaneous administration of tocilizumab, a monoclonal antibody against the IL-6 receptor, resulted in marked clinical and radiological improvement and sustained disease stabilization.

Conclusions

This case highlights the potential of IL-6 receptor inhibition with tocilizumab as an effective treatment strategy for refractory MOGAD.

大约一半髓鞘少突胶质细胞糖蛋白(MOG)抗体相关疾病(MOGAD)患者经历复发,最佳的复发预防策略仍在讨论中。白细胞介素-6 (IL-6)信号通路在MOGAD的发病机制中起着关键作用,其抑制已被认为是一种有前景的治疗方法。我们描述了一名18岁的难治性MOGAD男性患者,其特征是mri检测到的多个病变显示急性播散性脑脊髓炎(ADEM)样模式,其病情在托珠单抗治疗下显着改善。他的症状包括发烧、头痛、恶心、感觉异常、痛觉、嗜睡和癫痫发作。尽管多次静脉注射甲基强的松龙、血浆置换和静脉注射免疫球蛋白,他的病情仍未得到控制。每周皮下注射tocilizumab(一种针对IL-6受体的单克隆抗体)可显著改善临床和放射学,并维持疾病稳定。结论:该病例强调了托珠单抗抑制IL-6受体作为难治性MOGAD的有效治疗策略的潜力。
{"title":"Successful Treatment of Refractory Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease With Tocilizumab: A Case Report and Literature Review","authors":"Takahiko Katsuyama,&nbsp;Ryohei Horiguchi,&nbsp;Yuki Matsunaga,&nbsp;Akihiro Nishimachi,&nbsp;Keisuke Morihara,&nbsp;Hideyuki Takeuchi","doi":"10.1111/cen3.70040","DOIUrl":"https://doi.org/10.1111/cen3.70040","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Approximately half of patients with myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD) experience relapses, and optimal relapse-prevention strategies remain under discussion. The interleukin-6 (IL-6) signaling pathway plays a pivotal role in MOGAD pathogenesis, and its inhibition has been proposed as a promising therapeutic approach.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>We describe an 18-year-old male with refractory MOGAD characterized by multiple MRI-detected lesions showing an acute disseminated encephalomyelitis (ADEM)-like pattern, whose condition dramatically improved with tocilizumab. His symptoms included fever, headache, nausea, paresthesia, moria, somnolence, and seizure. Despite multiple courses of intravenous methylprednisolone, plasma exchange, and intravenous immunoglobulin, his condition remained uncontrolled. Weekly subcutaneous administration of tocilizumab, a monoclonal antibody against the IL-6 receptor, resulted in marked clinical and radiological improvement and sustained disease stabilization.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This case highlights the potential of IL-6 receptor inhibition with tocilizumab as an effective treatment strategy for refractory MOGAD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the Benefits of “Circle”: A Patient Support Program for Neuromyelitis Optica Spectrum Disorder for Patients Receiving Satralizumab Treatment 评估“Circle”的益处:接受Satralizumab治疗的视神经脊髓炎谱系障碍患者支持计划
Q4 Immunology and Microbiology Pub Date : 2025-11-18 DOI: 10.1111/cen3.70037
Kazuo Fujihara, Chiaki Sugita, Katsuhisa Yamashita, Yuta Kamei

Objectives

Although satralizumab, an interleukin-6 receptor inhibitor, effectively prevents relapses in neuromyelitis optica spectrum disorder (NMOSD), infections are reported to be the most common adverse reactions. To support Japanese patients receiving satralizumab, “Circle”—a 1-year patient support program—was developed. “Circle” provides educational materials, including information on NMOSD, satralizumab treatment, and potential infections occurring during treatment, thereby promoting the early detection and prevention of infection. We assessed the impact of the “Circle” program through a questionnaire-based patient survey.

Methods

Patients receiving satralizumab treatment who had completed 1 year in the program were invited to participate via mailed postcards between May 2023 and August 2024.

Results

Of the 657 patients who had completed 1 year post-enrollment and received the questionnaire, 236 (35.9%) responded. Among the responders, 95.3% continued satralizumab treatment. Overall, 68.6% of responders felt more positive about their NMOSD treatment, and 88.6% reported increased infection awareness. Among 209 responders who reported increased infection awareness, 76.6% became more conscious of infection control measures (e.g., handwashing and gargling), 54.1% started using a pulse oximeter for the early detection of respiratory tract infections, 50.2% started consulting their physician or nurse about physical changes, and 28.7% started daily monitoring of their body temperature.

Conclusions

The “Circle” program enhanced patient knowledge and improved infection control behaviors, potentially ensuring adherence to satralizumab treatment in patients with NMOSD. This initiative may play a crucial role in future treatment support.

尽管白细胞介素-6受体抑制剂satralizumab可以有效预防视神经脊髓炎谱系障碍(NMOSD)的复发,但据报道,感染是最常见的不良反应。为了支持接受satralizumab治疗的日本患者,开发了为期1年的患者支持项目“Circle”。“Circle”提供教育材料,包括NMOSD、satralizumab治疗和治疗期间发生的潜在感染的信息,从而促进感染的早期发现和预防。我们通过一项基于问卷的患者调查来评估“循环”计划的影响。方法在2023年5月至2024年8月期间,通过邮寄明信片的方式邀请接受satralizumab治疗1年的患者参与该项目。结果657例患者在入组1年后接受问卷调查,236例(35.9%)有应答。在应答者中,95.3%的患者继续接受satralizumab治疗。总体而言,68.6%的应答者对他们的NMOSD治疗感到更加积极,88.6%的应答者报告感染意识增加。在209名报告感染意识增强的应答者中,76.6%的人更加意识到感染控制措施(如洗手和漱口),54.1%的人开始使用脉搏血氧仪早期发现呼吸道感染,50.2%的人开始向医生或护士咨询身体变化,28.7%的人开始每天监测体温。“Circle”项目增强了患者的知识,改善了感染控制行为,有可能确保NMOSD患者坚持使用satalizumab治疗。这一举措可能在未来的治疗支持中发挥关键作用。
{"title":"Assessing the Benefits of “Circle”: A Patient Support Program for Neuromyelitis Optica Spectrum Disorder for Patients Receiving Satralizumab Treatment","authors":"Kazuo Fujihara,&nbsp;Chiaki Sugita,&nbsp;Katsuhisa Yamashita,&nbsp;Yuta Kamei","doi":"10.1111/cen3.70037","DOIUrl":"https://doi.org/10.1111/cen3.70037","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Although satralizumab, an interleukin-6 receptor inhibitor, effectively prevents relapses in neuromyelitis optica spectrum disorder (NMOSD), infections are reported to be the most common adverse reactions. To support Japanese patients receiving satralizumab, “Circle”—a 1-year patient support program—was developed. “Circle” provides educational materials, including information on NMOSD, satralizumab treatment, and potential infections occurring during treatment, thereby promoting the early detection and prevention of infection. We assessed the impact of the “Circle” program through a questionnaire-based patient survey.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients receiving satralizumab treatment who had completed 1 year in the program were invited to participate via mailed postcards between May 2023 and August 2024.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 657 patients who had completed 1 year post-enrollment and received the questionnaire, 236 (35.9%) responded. Among the responders, 95.3% continued satralizumab treatment. Overall, 68.6% of responders felt more positive about their NMOSD treatment, and 88.6% reported increased infection awareness. Among 209 responders who reported increased infection awareness, 76.6% became more conscious of infection control measures (e.g., handwashing and gargling), 54.1% started using a pulse oximeter for the early detection of respiratory tract infections, 50.2% started consulting their physician or nurse about physical changes, and 28.7% started daily monitoring of their body temperature.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The “Circle” program enhanced patient knowledge and improved infection control behaviors, potentially ensuring adherence to satralizumab treatment in patients with NMOSD. This initiative may play a crucial role in future treatment support.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen3.70037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145751241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unveiling Oversights in Hypothermia's Neuroprotective Mechanisms 揭示低体温的神经保护机制的疏忽
Q4 Immunology and Microbiology Pub Date : 2025-11-14 DOI: 10.1111/cen3.70039
Mona Hassan Ali Al Farhan, Javed Iqbal, Manal Chihab Al Deri
{"title":"Unveiling Oversights in Hypothermia's Neuroprotective Mechanisms","authors":"Mona Hassan Ali Al Farhan,&nbsp;Javed Iqbal,&nbsp;Manal Chihab Al Deri","doi":"10.1111/cen3.70039","DOIUrl":"https://doi.org/10.1111/cen3.70039","url":null,"abstract":"","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145751100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Experimental Neuroimmunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1